Loading...
Market
First Expansion Market for Gordian Bio by 2025
2
Resolution / Starting Odds
North America • 25%
Europe • 25%
Asia • 25%
Rest of World • 25%
Official company announcements or credible business news sources
Story
Gordian Bio Unveils $60M Platform for Age-Related Disease Therapies
Apr 28, 2024, 03:23 PM
Gordian Bio, co-founded by Martin Jensen and Leport five years ago, has officially launched its innovative platform designed to accelerate the development of therapies for age-related diseases. The biotech startup, which unveiled its platform yesterday, has raised $60 million to support its high-throughput in vivo screening platform. This platform allows for the simultaneous testing of hundreds of gene therapies in animal models that closely mirror human biology. The company aims to produce more effective therapies more quickly and cost-effectively while using fewer animals.
View original story
Similar markets
Low penetration (<1%) • 25%
Moderate penetration (1-3%) • 25%
High penetration (3-5%) • 25%
Very high penetration (>5%) • 25%
Only in livestock • 25%
Extended to other farm animals • 25%
Applied to industrial processes • 25%
Used in multiple sectors • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
< 10% adoption • 33%
10% to 30% adoption • 33%
> 30% adoption • 33%
Leader in biotech market • 25%
Top 5 in biotech market • 25%
Moderately successful • 25%
Struggles to scale • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Latin America • 25%
Successful phase 3 trial by another company • 25%
New regulatory approval • 25%
Major partnership or acquisition • 25%
Another failed trial • 25%
